Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
What Multiplex CRISPR Evidence Really Shows
2026-11-19
Multiplex CRISPR–Cas can coordinate perturbations at several genomic sites, but the same mechanism that enables large deletions and complex structural changes also increases uncertainty around repair outcomes, off-target effects, cellular stress and clinical delivery. The strongest evidence supports multiplex editing as a research strategy; therapeutic interpretation remains constrained by specificity, delivery, safety and access challenges.
When Research Context Changes an Editing Result
2026-11-19
The meaning of a genome-editing result depends on the biological question, model, comparator, and readout. Multiplex CRISPR studies illustrate why a sequence change can indicate a successful perturbation in one context but remain insufficient evidence for function, selectivity, or clinical benefit in another.
What Multiplexed CRISPR Can—and Cannot—Show
2026-11-18
A literature-focused analysis of how multiplexed CRISPR–Cas editing creates combinatorial perturbations, structural variants and regulatory changes, while distinguishing platform feasibility from therapeutic evidence.
What Multiplex CRISPR Comparisons Really Show
2026-11-18
Published comparisons support multiplex CRISPR as a flexible platform for coordinated genetic perturbation, but they do not establish uniform efficiency, specificity, or clinical safety across targets, cell models, or delivery systems. The strongest evidence concerns the range of outcomes the technology can produce; the largest uncertainties concern how reliably those outcomes can be interpreted.
Multiplex CRISPR: What the Evidence Shows
2026-11-17
A literature-focused analysis of how multiplex CRISPR–Cas editing creates coordinated genetic perturbations, structural variants, and regulatory changes, while examining specificity, delivery, cytotoxicity, and limits on translation.
Multiplex CRISPR: Evidence Beyond Single Targets
2026-11-17
A literature-focused analysis of how multiplex CRISPR–Cas editing extends genome perturbation from single-site knockout to combinatorial gene regulation and structural-variant modeling, while highlighting unresolved questions about repair outcomes, specificity, delivery, and clinical transferability.
How Multiplex CRISPR Changes Genome Interpretation
2026-11-16
Multiplex CRISPR–Cas systems are powerful because they connect programmable DNA targeting with the cell’s own repair pathways. The same mechanism that enables coordinated gene disruption and structural-variant modeling also creates interpretive challenges: phenotypes may reflect intended gene perturbation, cumulative DNA damage, unintended edits, or interactions among targets.
Multiplexed CRISPR–Cas: Reading the Evidence
2026-11-16
A literature-focused analysis of how multiplexed CRISPR–Cas systems extend genome editing from single-locus perturbation to coordinated gene disruption, structural-variant modeling, epigenetic regulation and multi-damage cell studies. It separates established mechanistic principles from emerging claims about delivery, specificity and AI-designed editors.
Multiplex CRISPR: From DNA Breaks to Cell Fate
2026-11-15
Multiplex CRISPR links guide-RNA-directed DNA damage to gene disruption, structural variation, coordinated transcriptional control and, in some contexts, selective cell loss. The strongest evidence supports mechanistic feasibility, while quantitative performance, specificity and applicability remain dependent on the editing architecture and cellular model.
NHE1 and Octanal in Macrophage Atherosclerosis
2026-11-14
A mouse and macrophage study links octanal–Olfr2 signaling to NHE1 activation, calcium elevation, oxidative stress, inflammasome-associated inflammation, foam-cell formation, and plaque progression. The evidence supports NHE1 as a mechanistic downstream effector in the tested models, while leaving important questions about pathway ordering, pharmacological specificity, and relevance to human disease.
When Context Changes What a CRISPR Result Means
2026-11-13
A CRISPR outcome can signify a molecular edit, a structural rearrangement, altered gene regulation, or cell selection depending on the model, target architecture, delivery context, and readout. This editorial examines how those contexts constrain interpretation of multiplex genome-editing findings.
When Context Changes What CRISPR Results Mean
2026-11-13
A genome-editing result does not have a fixed meaning outside its model, perturbation design, readout, and delivery context. This editorial examines how the same CRISPR platform can support different claims about molecular editing, structural variation, gene function, cell viability, and translational feasibility.
What Multiplex CRISPR Evidence Shows
2026-11-12
A literature-focused analysis of how multiplexed CRISPR–Cas systems enable simultaneous gene perturbation, structural-variant modeling, epigenome editing and combinatorial functional screens. The review supports a strong mechanistic case for multiplexing while emphasizing unresolved problems in specificity, delivery, cellular damage and clinical transferability.
What Multiplex CRISPR Evidence Actually Shows
2026-11-12
Published comparisons support multiplex CRISPR as a flexible framework for coordinated gene disruption, structural-variant modeling and transcriptional regulation, but they do not establish a universal advantage across cell types or readouts. The strongest unresolved issues are cumulative off-target damage, delivery constraints, tradeoffs between specificity and activity, and the limited basis for extrapolating broad human-cell findings to any particular cell-line preparation.
Multiplex CRISPR: What the Evidence Shows
2026-11-11
Multiplex CRISPR can generate coordinated genetic perturbations, including deletions and other structural variants, but the same DNA-damage burden that enables these outcomes can confound functional interpretation. The strongest evidence supports technical feasibility; claims about specificity, therapeutic selectivity, or performance in any particular cell preparation require narrower, primary-study evidence.